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One major problem of small-diameter vascular
grafts is the high occlusion rate.1 Undoubtedly, 
the best arterial substitute remains the autologous ves-
sel, but only a limited number of suitable arteries and
veins are available. Thus, the use of prosthetic small-
diameter prostheses with known inferior patency rates
is unavoidable.2,3 Prosthetic materials are thrombo-
genic and cause platelet adhesion and activation of the
coagulation cascade on the graft.4,5 In humans, re-
endothelialization is limited to the ingrowth of
approximately 1 cm at each anastomosis.6 The seeding
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Background: Small-diameter vascular grafts tend to have an early and high occlusion
rate. Cell seeding on the luminal surfaces of small-diameter vascular prostheses may pro-
vide an antithrombotic lining and improve both the short-term and the long-term
patency rates. We studied the net results of procoagulant and anticoagulant properties
of seeded grafts under blood-flow conditions, and we compared the different available
types of donor cells.
Methods: Monolayers of liposuction-derived cultured human microvascular endothelial
cells (MVECs), human adult endothelial cells (HAECs), human umbilical vein endothe-
lial cells (HUVECs), and human mesothelial cells (MCs) that had been seeded on
expanded polytetrafluoroethylene (ePTFE) grafts were perfused with marginally antico-
agulated blood (20 U/mL low molecular weight heparin; shear rate, 400/s, 10 minutes)
or with non-anticoagulated blood (shear rate, 100/s, 5 minutes). The thrombin and fi-
brin generation in time was studied with the measurement of the plasma levels of pro-
thrombin fragment 1 and 2 (F 1+2) and of fibrinopeptide A (FPA). The plain ePTFE
graft was taken as a control.
Results: When the seeded MCs were perfused with recirculating anticoagulated blood, a
linear generation of F 1+2 in time was seen, with high levels of F 1+2 and FPA after 10
minutes (4.38 nmol/L and 362 ng/mL, respectively). Allopurinol was added, and the
MCs generated less F 1+2 than the HAECs (0.7 nmol/L vs 1.86 nmol/L; P < .05). No
fibrin formation was seen. The MVECs generated low amounts of F 1+2 (0.7 nmol/L;
10 minutes), and the HUVECs and the plain ePTFE graft generated the lowest amounts
of F 1+2 (0.26 and 0.25 nmol/L, respectively). When the MCs were perfused with non-
anticoagulated blood, high amounts of thrombin and fibrin were generated immediate-
ly and constantly and could not be decreased with allopurinol. The perfusion of the plain
ePTFE graft showed a dramatic increase in F 1+2 and FPA levels towards the end of the
experiments. The seeded HAECs, HUVECs, and MVECs inhibited this increase. These
results were confirmed by means of scanning electron microscopy.
Conclusion: Vascular prostheses that are seeded with cultured MCs are highly procoagu-
lant. Standard ePTFE graft prostheses also initiate coagulation, which supports the idea
of cell seeding. The endothelial cells, of which the MVECs are the most readily available,
seem to preserve their anticoagulant properties after being seeded on vascular grafts.
(J Vasc Surg 1998;28:1094-1103.)
From the Departments of Surgery (Drs Hedeman Joosten,
Verhagen, van Vroonhoven, and Eikelboom) and Haematology
(Heijnen-Snyder and Drs Hedeman Joosten, Verhagen, Sixma,
and de Groot), University Hospital Utrecht.
Supported by grants from the Dutch Heart Association and the
University Hospital Utrecht.
Reprint requests: P. Ph. A. Hedeman Joosten, MD, Department
of Vascular Surgery, University Hospital Utrecht, Postbus
85500 3508 GA, Utrecht, The Netherlands.
Copyright © 1998 by The Society for Vascular Surgery and
International Society for Cardiovascular Surgery, North
American Chapter.
0741-5214/98/$5.00 + 0 24/1/93338
of the luminal surface with endothelial cells (ECs) may
give a prosthetic graft a biologic lining that might con-
tribute to the balance of the hemostatic process.
Unfortunately, adult human HLA-compatible ECs,
which are the natural lining of the arteries, are only
scarcely available. Most laboratory and clinical experi-
ence has been gained with HLA-compatible adult
endothelial cells (HAECs) that were harvested from
large veins. Cell seeding with HAEC, however, has a
major drawback because of the fact that the cell num-
bers in the primary isolates are not high enough to
seed a graft with a confluent layer of cells. So, it
becomes necessary to first grow these cells in vitro
before they can be seeded on prosthetic grafts.
Therefore, attention has turned to alternative cell
sources. The mesothelial cells (MCs) are isolated easi-
ly in high numbers from the omentum of the candi-
date for graft implantation, and they grow consider-
ably faster to a confluent monolayer than do ECs. The
MCs have hardly any growth failures, and they possess
antithrombotic and fibrinolytic properties.7-12 Recent
work in our laboratory showed that the MCs express
substantial amounts of tissue factor after isolation and
culture, which is in contrast to the in vivo situa-
tion.13,14 With the change of the culture conditions
and with the inhibition of the formation of free radi-
cals, their tissue factor expression was inhibited by
90%.14 Microvascular endothelial cells (MVECs) are
abundantly available from subcutaneous fat tissue. The
procurement is minimally invasive (liposuction), and
the isolated cell numbers are so high that single stage
seeding and sodding procedures are possible.15- 20
From previous studies, we have learned that MCs
and MVECs do form a monolayer on fibronectin-
coated vascular grafts. This monolayer was shown to
be resistant to physiologic shear stress.21,22 The aim
of this study was the examination of thrombin and
fibrin formation with MC-seeded and EC-seeded
grafts in whole blood under flow conditions.
METHODS
Isolation and culture of cells
Mesothelial cells. Small pieces of human omen-
tum (±20 cm2) were obtained from patients who
underwent abdominal surgery. The pieces of omen-
tum were washed with a phosphate-buffered saline
solution (PBS) and were transferred to a prewarmed
PBS that contained 0.05% trypsin and 0.02% ethyl-
enediamine tetraacetic acid (Gibco Europe Ltd,
Paisley, United Kingdom). After 15 minutes of incu-
bation with gentle shaking at 37°C, the detached
MCs were pelleted with centrifugation at 1200 rpm
for 8 minutes. The pelleted cells were resuspended in
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medium 199 (M199), which contained 10% fetal calf
serum (FCS; Gibco), and were cultured in 75-cm2
polystyrene flasks (Costar, Cambridge, Mass), which
had been precoated with fibronectin. The cells were
grown in a humidified 5%-CO2 incubator at 37°C.
The culture medium was changed every other day.
Morphologically, the MCs formed a confluent
monolayer of cells with a typical cobblestone appear-
ance in about 5 days. The identity of the MCs was
controlled with the demonstration of the presence of
intracellular cytokeratins 6 and 18 and of the absence
of von Willebrand factor with monoclonal antibodies
(Dako-Ck1, LP 34, Dako, Glostrup, Denmark).13,14
Microvascular endothelial cells. Human sub-
cutaneous fat was obtained through liposuction or
abdominoplasty. The protocol that was described by
Williams et al16 was followed with some minor mod-
ifications. In the case of abdominoplasty, the fat tis-
sue was minced with a scalpel or scissors to a size that
was comparable with the liposuction material. After 1
wash step with sterile PBS, the fat was transferred to
a prewarmed (37°C), filtered collagenase solution
that contained 4 mg/mL of collagenase type I
(Sigma, St Louis, Mo) and 4 mg/mL of bovine
serum albumin (Sigma) in a PBS (10 mL of fat + 10
mL of collagenase per tube). This was followed by a
30-minute incubation with gentle shaking at 37°C.
The resultant slurry was sifted through a 1-mm sieve
to eliminate the resting lumps and the fibrous
strands, after which it was centrifuged at 1200 rpm
for 10 minutes. The adipocytes at the top of the tube
and the collagenase solution were decanted, and the
pellet was resuspended in M199, which contained
penicillin (100 units/mL), streptomycin (100
g/mL), and amphotericin B (4 m g/mL, M199;
Gibco). The cell suspension was centrifuged once
more at 1000 rpm for 5 minutes, after which it was
resuspended in 12 mL of tissue culture medium
(M199, with aforementioned antibiotics, 20% FCS, 5
IU/mL heparin [Leo Pharmaceutical, Weesp, The
Netherlands], and 50 m g EC growth factor [prepared
in-house from bovine hypothalamus]). The cells
were plated onto the 75-cm2 fibronectin precoated
polystyrene flasks and grown in a fully humidified
5%-CO2 incubator at 37°C. The culture medium was
changed every other day. The morphology varied
between cobblestone and more elongated forms, and
the identity of the cells was controlled with the
demonstration of positive immunostaining for
endothelial markers—von Willebrand factor, Ulex
Europeaus 1, CD-31, EN-4.
Human umbilical vein endothelial cells.
Human umbilical vein endothelial cells (HUVECs)
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were isolated according to Jaffe et al23 with some
minor modifications.24,25 The HUVECs were iden-
tified by the presence of von Willebrand factor. The
HUVECs were grown in RPMI-1640 (Gibco), with
20% human serum (HS; pooled from 20 healthy
donors) and antibiotics with the same conditions as
were described for the culture of the MCs. They
formed a monolayer in about 7 to 10 days.
Human adult endothelial cells. The HAECs
were isolated from pieces of human aorta. The
pieces of aorta were placed in prewarmed trypsin for
15 minutes, with the luminal surface facing down-
wards. The luminal surface then was scraped gently
with a rubber policeman and rinsed with the culture
medium. The mixture of trypsin, culture medium,
and cells was centrifuged at 1100 rpm for 5 minutes.
The cell pellet was resuspended in RPMI-1640,
which contained 10% HS, 0.15 mg/mL EC growth
supplement (obtained from bovine hypothalamus),
5 IU/mL of heparin, and antibiotics (penicillin,
streptomycin, and amphotericin B). The cells were
cultured in a 25-cm2 culture flask (Costar) with the
same conditions as were described above. A mono-
layer was formed in about 2 weeks. The second pas-
sage cells were used for the experiments and were
identified by the presence of von Willebrand factor.
At least 24 hours before a perfusion experiment, the
culture medium for HUVECs and HAECs was
changed to M199 with 10% FCS, which was the
same as was used for the MCs. In some experiments,
the cells were incubated with a culture medium that
contained 4 mmol/L of allopurinol (Sigma) or with
a culture medium that contained 10% HS, for a time
period of 24 to 48 hours before a perfusion.
Perfusion chamber
For the perfusion experiments, we used a newly
developed chamber (Fig 1) on the basis of a well-
described and often-used model.26,27 Two pieces of
sterile expanded polytetrafluoroethylene (ePTFE) vas-
cular grafts (Fig 1, II; W. L. Gore & Assoc, Flagstaff,
Ariz) of standard thickness (0.64 mm) and internodal
distance (30 m m) were cut (18 mm · 21 mm) and
immobilized on the 2 large caps (Fig 1, I) with the
luminal surface facing upwards. The rectangular cham-
ber (Fig 1, III) was placed over these 2 caps and sealed
with rubber O-rings. On the upper side of the flow
chamber, 2 smaller holes were made in which either
the seeding cap (Fig 1, IV) or the perfusion cap (Fig
1, V) could be sealed. In the seeding caps, a small rec-
tangular chamber (1.25 cm2) that could be placed on
the ePTFE graft surface was made, which allowed the
cells to be seeded on a precisely described area com-
pletely in the lane of the flow. After a seeding proce-
Fig 1. Diagram of seeding/perfusion chamber. I, Large caps on which pieces of ePTFE pros-
theses (II) were immobilized. The rectangular chamber (III) was placed over these 2 caps,
which exposed 10 mm · 18 mm of graft surface to flow. The seeding caps (IV) or perfusion
knobs (V) could be placed in upper side of chamber.
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dure, the seeding caps were changed for the perfusion
caps, which gave the roof of the perfusion chamber a
smooth surface. The surface of each of the pieces of
ePTFE graft exposed to the flow measured 10 mm ·
18 mm, and the height of the flow chamber measured
1.0 mm.
Graft seeding
Immediately before an experiment, a monolayer of
MCs, MVECs, HUVECs, or HAECs (all second pas-
sage) was detached by trypsinization, counted with a
Coulter Counter (Coulter Electronics Ltd, Luton,
United Kingdom), and resuspended in M199 that
contained 10% FCS (with or without allopurinol, as
stated) or 20% FCS, depending on the tissue culture
medium. The cylindrical hole (diameter, 6 mm) in the
seeding cap gave access to the rectangular chamber,
with 1.25 cm2 of the prosthetic material exposed.
Fibronectin was purified from human plasma as
described before28 and was used to precoat the grafts
(50 m g/mL = 20 m g/cm2) for 1 hour at 37°C. The
MCs, MVECs, HUVECs, and HAECs were seeded (2
· 105 cells/cm2) and allowed to attach for 4 hours.
Subsequently, the seeded grafts were rinsed thorough-
ly with N-2-hydroxyethylpiperazine-N-2-ethanesul-
fonic buffered saline solution (HBS; 10 mmol/L N-2-
hydroxyethylpiperazine-N-2-ethanesulfonic, 145
mmol/L NaCl, pH 7.4) to remove the unattached
cells, the seeding cap was exchanged for the perfusion
cap, and the perfusion chamber was connected to the
flow circuit. The number of cells that were attached to
the prostheses at the beginning of the perfusion exper-
iments and the detachment of seeded cells as a result
of shear forces have been studied before and were
described in detail elsewhere.21,22
Flow circuit and perfusions
With the change of the seeding cap for the
smooth perfusion cap, the seeded grafts could be
perfused without manipulation, with possible cell
loss as a consequence. The hemodynamic parameters
of the flow circuit were calculated with the work 
of Milnor29 and Muggli et al.30 The maximum
Reynolds number in our flow circuit was 95, so the
calculations could be on the basis of laminar flow.
Two different perfusion models were studied: a
model in which recirculated, marginally anticoagu-
lated blood was used; and an ex vivo model in which
non-anticoagulated blood was used.
Recirculation perfusions. The flow circuit as
used for the recirculation perfusions is shown in Fig 2.
A 50-mL tube of freshly drawn blood from healthy
donors who denied the use of any medication for at
least 2 weeks before the donation. The blood was anti-
coagulated with low molecular weight heparin (20
U/mL; Fragmin, Kabi Pharmacia AB, Sweden) and
was placed in a waterbath at 37°C. The cap of the 50-
mL tube had 1 inlet port and 1 outlet port. The out-
let port was connected to a roller pump, which was
capable of delivering flow rates between 2.8 and 280
mL/min (model 2010, Verder, Vleuten, The
Netherlands). To achieve a steady flow, a funnel was
connected between the roller pump and the perfusion
chamber. The distal end of the perfusion chamber was
connected to the inlet port to complete the circuit. All
of the connections were made with a silicon tubing.
The experiments were done at a shear rate of 400/s
(38 mL/min), which is characteristic for medium-
sized arteries. Before each experiment, the pump
speed was calibrated and a new tubing was used.
Before use, the new tubing first was rinsed with HBS.
Recirculation perfusions were performed for 10 min-
utes. After perfusion, the whole system was rinsed with
50 mL of prewarmed HBS. The pieces of seeded
ePTFE graft were collected and fixed for scanning
electron microscopic (SEM) evaluation.
Ex-vivo perfusions. Non-anticoagulated blood
was drawn directly through the chamber from the
antecubital veins of healthy donors with a 19-G nee-
dle31 (Fig 3). The blood was aspirated over the seed-
ed prostheses at a constant flow rate of 10 mL/min
with a syringe pump (Harvard Apparatus, South
Natick, Mass) that was placed distally to the perfusion
chamber. The blood flow rate of 10 mL/min result-
ed in a wall shear rate of 100/s at the cell layer on the
prostheses. This shear rate reflects the flow conditions
in the veins and favors fibrin-rich clot formation.32 All
of the healthy volunteers denied taking any medica-
tion in the 14 days before the donation. The platelet
Fig 2. Diagram of flow circuit that was used for recircu-
lation perfusions.
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counts, the leucocyte counts, and the hematocrit were
all within the normal ranges. At the end of a 5-minute
perfusion, the prewarmed HBS was perfused at the
same flow rate for 40 seconds. The flow chamber was
disconnected, and the pieces of ePTFE graft vascular
prostheses were fixed for evaluation with SEM.
Determination of thrombin and fibrin formation
For the in vitro perfusions, the blood samples
(450 m L) were collected from the container imme-
diately before the recirculating perfusions (0-value),
after every minute up to 5 minutes, and after 10
minutes during the experiments.
During the ex vivo perfusions, 450-m L blood sam-
ples were collected directly through the wall of the sil-
icon tubing with a 25-G needle. The first sample was
taken proximal to the perfusion chamber after the first
few mililiters had passed (0-value), and samples then
were taken directly distal to the perfusion chamber
after every minute. At the end of the perfusion,
another proximal sample was collected. All of the
samples were mixed immediately with 50-m L of ethyl-
enediamine tetraacetic acid (100 mmol/L) and cen-
trifuged at 3500 rpm for 5 minutes, and the aliquots
of plasma were stored at –20°C until assayed.
Prothrombin fragment 1+2 (F 1+2) was mea-
sured with a commercially available radioimmunoas-
say (Enzygnost–F 1+2, Behring, Germany). A radio-
immune assay kit was used for the fibrinopeptide A
(FPA) measurements (RIA-mat FPA, Byk-Sangtec
GmbH & Co KG, Dietzenbach, Germany).
As a control, both the recirculating and the ex
vivo perfusions were performed with blank ePTFE
graft prostheses (without cells). To determine the
amount of F 1+2 that was generated during a perfu-
sion experiment, the 0-value was subtracted from
the amount of F 1+2 that was measured in all of the
other samples from the same experiment.
Morphologic examination
Each graft that was prepared for SEM was rinsed
with HBS, fixed in 2% glutaraldehyde for 1 hour, post-
fixed in 1% osmium tetroxide (Sigma) for 1 hour, and
then dehydrated through increasing concentrations of
ethanol (50% to 100%). The samples were critical-
point dried (CPD 010, Balzers Union, Lichtenstein),
Fig 3. Ex vivo perfusion. Non-anticoagulated blood is
drawn from antecubital vein through perfusion chamber.
Blood samples are taken through tubing. After the exper-
iment, perfused graft will be taken out of perfusion cham-
ber and fixed for scanning.
Fig 4. Surfaces of ePTFE graft perfused for 5 minutes
with non-anticoagulated blood (shear rate 100/s). 
A, ePTFE graft seeded with MVECs demonstrates almost
no fibrin generation and minimal thrombocyte aggrega-
tion. B, Standard plain ePTFE graft shows fibrin forma-
tion and thrombocyte aggregation. 
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sputtered with gold (SCD 040, Balzers Union), and
finally examined with SEM (Camscan, Cambridge,
United Kingdom).
Statistical analysis
The results are expressed as the mean ± the stan-
dard deviation of the mean, unless otherwise stated.
A nonparametric test was used to determine the sig-
nificant differences between the groups (Mann-
Whitney test). A P value of < .05 was considered sig-
nificant.
RESULTS
Recirculation perfusions
Procoagulant activity of different surfaces. A
summary of the amount of F 1+2 that was generat-
ed after 5 and 10 minutes of perfusion with the most
relevant conditions is shown in Table I. The MCs
generated the highest values of F 1+2 in 10 minutes
(4.38 ± 1.1 nmol/L). When allopurinol was added
to the culture medium to reduce the tissue factor
expression, significantly less F 1+2 was generated by
the MCs (0.70 ± 0.38 nmol/L; P = .01, vs FCS).
When the MCs were cultured in the tissue culture
medium that contained 10% HS instead of 10% FCS,
the F 1+2 values rose significantly (6.25 ± 0.52
nmol/L).
The HAECs that were seeded on the ePTFE graft
prosthesis generated significantly lower amounts of F
1+2 than the MCs that were cultured in FCS (1.86 ±
0.22 nmol/L; P < .05) but significantly higher
amounts when compared with the MCs that were
treated with allopurinol (P < .05). The HAECs did
not respond to the allopurinol treatment. The
MVECs that were seeded on the ePTFE graft gener-
ated comparable amounts of F 1+2 (0.70 ± 0.30
nmol/L) to the MCs that were treated with allopuri-
nol (0.70 ± 0.38 nmol/L).
The lowest levels of F 1+2 were measured after
the perfusion of the prostheses that were seeded
with HUVECs (0.26 ± 0.07 nmol/L) or when the
blank prostheses were perfused (0.25 ± 0.07
nmol/L). These F 1+2 values were significantly
lower than all of the others (P < .05 vs MCs with
allopurinol or MVECs).
High amounts of FPA were generated after 5 and
10 minutes by the MCs that were cultured with 10%
HS or 10% FCS (836 ± 76 ng/mL and 362 ± 51
ng/mL, respectively, after 10 minutes). No increase
in the FPA levels was seen during all of the other
experiments. The mean FPA value in the blood before
perfusion was 14 ng/mL (range, 9 to 22 ng/mL),
which is the same as was described by others.33
Morphologic examination. All of the flow sur-
faces were fixed and examined with SEM. After the
perfusion of the MCs, which were cultured in the
presence of 10% FCS or 10% HS, a layer of fibrin was
deposited parallel to the blood flow on the complete
surface of the seeded prostheses, with platelet aggre-
gates adhering to the fibrin strands and red blood
cells captured in the fibrin meshwork. When allo-
purinol was added to the culture medium, signifi-
cantly less fibrin or aggregates were found. In the
cases of ePTFE grafts that were seeded with
MVECs, HUVECs, or HAECs, there were clearly
less fibrin and thrombocyte aggregates when com-
Table I. Recirculation perfusion: plasma levels of prothrombin fragment 1+2, and fibrinopeptide A after 5
and 10 minutes (mean ± standard deviation of the mean)
F 1+2 (nmol/L) FPA (ng/mL)
Cell types Additions N 5 minutes 10 minutes 5 minutes 10 minutes
MC — 5 2.40 ± 0.58 4.38 ± 1.1* 197 ± 101 362 ± 51
Allopurinol 5 0.43 ± 0.29 0.70 ± 0.38 NI NI
HAEC — 4 0.66 ± 0.21 1.86 ± 0.22 NI NI
Allopurinol 4 0.78 ± 0.24 1.85 ± 0.43 NI NI
MVEC — 10 0.47 ± 0.17 0.70 ± 0.30† NI NI
HUVEC — 5 0.22 ± 0.16 0.26 ± 0.07† NI NI
No cells — 4 0.19 ± 0.09 0.25 ± 0.07† NI NI
F 1+2, prothrombin fragment 1+2; FPA, fibrinopeptide; N, number of perfusions; MC, human mesothelial cells; HAEC, human adult
endothelial cells; MVEC, human microvascular endothelial cells; HUVEC, human umbilical vein endothelial cells; NI, no increase mea-
sured.
*P = .01, compared with mesothelial cells with allopurinol.
†P < .05.
The total amount of prothrombin fragment 1+2 generated during the 10-minute perfusion was calculated by multiplying the end-con-
centration of prothrombin fragment 1+2 by the total volume (50 mL). Recirculation perfusions were performed with marginally anti-
coagulated blood with a flow rate of 38 mL/min (shear rate, 400/s).
JOURNAL OF VASCULAR SURGERY
1100 Joosten et al December 1998
pared with non-allopurinol treated MCs. The
unseeded ePTFE grafts showed higher platelet
aggregation than the seeded grafts.
Ex vivo perfusions
Thrombin generation. To better evaluate the
non-thrombogenic properties, the seeded grafts
were subjected to ex vivo perfusions, with non-anti-
coagulated blood. Pieces of the ePTFE grafts were
seeded with MCs (with or without allopurinol), with
MVECs, with HAECs, or with HUVECs. The blank
pieces of the ePTFE graft prostheses were taken as
controls.
During the ex vivo perfusions, 7 samples were
taken by puncture through the wall of the silicon
tubing—2 proximal to the chamber and 5 distal to
the chamber, all close to each other.
Table II shows the generation of F 1+2 and FPA
during the ex vivo perfusions. Although a large vari-
ation was seen within each of the 6 experimental
conditions, the MCs generated the highest levels of
F 1+2.
For the MCs, the F 1+2 values were maximal
within 1 or 2 minutes without an increase or reduc-
tion during the following minutes. The inhibitory
effect of allopurinol on F 1+2 generation was less
clear in these experiments and, at certain time
points, non-existing. When MVECs, HAECs,
HUVECs, or plain prostheses were used, lower val-
ues of F 1+2 were found, although all of the condi-
tions clearly showed generation of F 1+2 towards
the end of the experiments.
The concentration of F 1+2 that was measured
proximal to the chamber (t = 0) was always below
1.1 nmol/L and was subtracted from all other values
from the same donor. The F 1+2 concentration that
was measured in the control samples taken proximal
to the chamber at the end of the perfusions (t = 5
minutes) was never more than 0.2 nmol/L above
the value at t = 0. So the generation of F 1+2 during
an experiment was mainly a result of the (seeded)
prostheses in the chamber.
In the case of the perfusion of MCs or of MCs
and allopurinol, the FPA levels corresponded with
the rise in F 1+2. The HUVECs, the HAECs, and
the MVECs, however, did not translate their higher
levels of F 1+2 at 5 minutes into such a high rise in
FPA as seen with the MCs or with the plain ePTFE
grafts (P < .05 MCs, MCs and allopurinol, or ePTFE
grafts vs HAECs, HUVECs, or MVECs).
Morphologic examination. After the perfusion
of the seeded MCs, a thick layer of fibrin covered the
complete surface of the prostheses, with platelet
aggregates adhering to the fibrin meshwork. No
morphologic differences were seen when the MCs
were treated with allopurinol before the perfusion.
After the perfusion of the EC-seeded prostheses
(HUVECs, HAECs, and MVECs) or of the plain
ePTFE graft prostheses, the fibrin strands, although
in lesser numbers as compared with the MCs, were
seen all over the perfused surface in the direction of
the flow, but the cells or the plain prostheses were
clearly visible.
DISCUSSION
The original idea of EC seeding was the
improvement of the patency of prosthetic small-
diameter grafts by the establishment of a biologic
Table II. Ex-vivo perfusion: plasma levels of prothrombin fragment 1+2 and fibrinopeptide A after 1 and
5 minutes (mean ± standard error of the mean)
F 1+2 (nmol/L) FPA (ng/mL)
Cells N 1 minute 5 minutes AUC (nmol/L·minutes) 1 minute 5 minutes
MC 4 3.37 ± 2.47 3.0 ± 1.61 14.44 ± 2.9 1953 ± 154 1189 ± 308
MC+All 5 1.48 ± 1.8 2.43 ± 2.1 10.67 ± 3.6 1030 ± 535 1835 ± 419
MVEC 10 0.06 ± 0.02 2.70 ± 0.79 7.10 ± 2.2 38.4 ± 16.4 527 ± 109* 
HAEC 5 0.05 ± 0.03 4.47 ± 1.57 8.46 ± 2.7 22 ± 10.7 758 ± 173*
HUVEC 5 0.19 ± 0.08 1.70 ± 0.49 1.49 ± 0.42 222 ± 88 696 ± 344*
Plain ePTFE 4 0.09 ± 0.14 0.25 ± 0.07 0.93 ± 0.33 16 ± 4 1653 ± 550
F 1+2, prothrombin fragment 1+2; FPA, fibrinopeptide; N, number of perfusions; MC, human mesothelial cells; HAEC, human adult
endothelial cells; MVEC, human microvascular endothelial cells; HUVEC, human umbilical vein endothelial cells; NI, no increase mea-
sured.
*P = .01, compared with mesothelial cells with allopurinol.
†P < .05.
The total amount of prothrombin fragment 1+2 generated during the 10-minute perfusion was calculated by multiplying the end-con-
centration of prothrombin fragment 1+2 by the total volume (50 mL). Recirculation perfusions were performed with marginally anti-
coagulated blood with a flow rate of 38 mL/min (shear rate, 100/s).
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antithrombotic lining on the luminal surface of the
graft. This process has reached the phase of clinical
evaluation, and encouraging results have been
reported.34,35 The major problems in all of these
studies were the limited availability and the poor
growth of the human HLA-compatible ECs. The
MCs came into focus as a possible alternative
because they are anti-thrombotic, fibrinolytic, and
anticoagulant in vivo.7-13 Unfortunately, procoagu-
lant activity is induced on MCs by isolation and cul-
ture and was found to be caused by an increased
expression of tissue factor.13 We have shown that tis-
sue factor expression can be decreased to the same
level as measured on adult ECs by changing culture
conditions and inhibiting the formation of free rad-
icals with allopurinol, a xanthine oxidase inhibitor.14
The microvascular cells that were isolated from fat
tissue are another alternative to adult ECs. They are
abundantly available in human beings, and they rep-
resent a source of cells large enough for single-stage
cell seeding without the need for prior culture. In
this study, we investigated the net result of procoag-
ulant and anticoagulant activities of different avail-
able cell types that were seeded on vascular prosthe-
ses under flow conditions with whole blood.
For the perfusion experiments, we first used low
molecular weight heparin–anticoagulated whole
blood and measured the prothrombin activation
(measured by F 1+2) and thrombin cleavage of fi-
brinogen (measured by FPA). We demonstrated that
the MCs that were cultured in medium that con-
tained 10% FCS or HS are highly procoagulant
because high levels of F 1+2 and FPA were found and
100% fibrin-coverage of the cells was seen by SEM.
The generation of F 1+2 was linear in time, and a
mean F 1+2 generation of 4.38 nmol/L after 10
minutes meant that about 0.3% of the total amount
of prothrombin (physiologic concentration, 1.4
m mol/L) was activated after 10 minutes. When allo-
purinol was added to the culture medium and the
cells were allowed to attach for 4 hours, 0.7 nmol/L
of F 1+2 was generated, and no fibrin was seen with
SEM. Apparently, 0.05% activation of prothrombin
was insufficient for fibrin generation.
Although the tissue factor expression of the allo-
purinol-treated MCs equalled the level that was mea-
sured on the cultured adult ECs,14 the generation of
F 1+2 was significantly lower. A possible mechanism
for this could be the high expression of thrombo-
modulin on MCs, which we demonstrated before.36
In the ex vivo perfusion system, we could mea-
sure the net result of the procoagulant and antico-
agulant properties of seeded cells to its full extent
because no anticoagulants were present. We chose to
study the following cell types that showed the low-
est F 1+2 generation after seeding and perfusion
with anticoagulated blood: HUVECs, which are
known to express virtually no tissue factor when
unstimulated;37 MVECs, which we demonstrated to
be comparable with HUVECs concerning tissue fac-
tor expression; and MCs that were treated with
allopurinol. Furthermore, MCs that were grown in
10% FCS were chosen as a positive control because
we demonstrated previously that these cells express
substantial amounts of tissue factor.13 The plain
ePTFE graft was chosen as control.
The significant decrease in procoagulant activity
when MCs were treated with allopurinol could not
be seen during the ex vivo perfusions.
The plain ePTFE graft prostheses performed well
during the first few minutes of the ex vivo perfusion.
Yet after a few minutes, the activation of prothrom-
bin started, high levels of FPA were found, and SEM
showed fibrin strands and platelet adherence on the
surface of the prostheses after 5 minutes. This under-
lined the need for an antithrombotic biologic lining
on the graft. When the HUVECs, HAECs, and
MVECs were seeded and perfused, generation of F
1+2 and FPA also was found. Although this genera-
tion started earlier than when the plain ePTFE graft
was perfused, it did not show the enormous increase
in both F 1+2 and FPA towards the end of the exper-
iment. Significant differences between the 2 surfaces
therefore may only be obtained when longer ex vivo
perfusions are performed.
The plain ePTFE graft performed well with
respect to its procoagulant activities when perfused
with anticoagulated blood, but, when native blood
was used, it performed poorly. This observation
would lead one to conclude that the study of graft
performance with anything but non-anticoagulated
blood might lead to misleading results.
We believe that there is no intrinsic difference in
surface procoagulant effect between the 2 perfusion
models that we used. However, it is likely that the
observations in the recirculating perfusions are
mainly heparin-induced. In the ex vivo model, there
is no inhibition of coagulation, which makes it a
more sensitive model to look at any existent proco-
agulant effect.
With a perfusion system that was developed to test
vascular grafts in a human system, we demonstrated in
this study that ePTFE vascular grafts that are seeded
with MCs are highly procoagulant. We also showed
that plain prostheses initiate coagulation during per-
fusions with native blood. We therefore think that the
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patency rates of small-diameter prostheses can indeed
be improved by lining them with a biologic lining. In
this study, we only measured early events and not a
steady state. To perform longer perfusions, which are
necessary to study steady state levels, one has to anti-
coagulate. This will, however, have a drastic effect on
the predictability. Despite the theoretical advances of
MCs over ECs, they do not seem to perform satisfac-
torily in vascular surgery, unless their procoagulant
properties are seriously downregulated. HUVECs
perform well in vitro, have a relatively quick growth
rate but obviously cannot be harvested in the group
of patients in need of vascular surgery. Adult ECs still
are used most often and are considered the gold stan-
dard by most cell-seeding groups. Microvascular ECs,
however, are available in much larger numbers
through minimally invasive surgery, can be cultured
first or used immediately, and show comparable
results with adult ECs when seeded.
We thank Stuart K. Williams and coworkers at the
Section of Surgical Research, University of Arizona, for
sharing with us their extensive knowledge relating to the
isolation, the identification, and the culture of microvas-
cular endothelial cells.
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